No suitable mouse model is available for studying chronic liver disease caused by hepatitis C virus (HCV). CD81, claudin-1, scavenger receptor class B type I, and occludin were recently reported to be the important factors in HCV entry into hepatocytes. We made transgenic mice (Alb-CCSO) expressing the four human proteins and examined whether HCV from a patient serum or HCV pseudoparticles (HCVpp) were capable of infecting them. HCV was not detected in the mouse serum after injecting the mice with HCV from a patient serum. We also found no indications of HCVpp entry into primary hepatocytes from Alb-CCSO mice. In addition, HCV-infectible Hep3B cells were fused with HCV-resistant primary mouse hepatocytes and the fused cells showed 35-fold lower infectivity compared to wild-type Hep3B cells, indicating that primary mouse hepatocytes have the inhibitory factor(s) in HCVpp entry. Our results suggest that the expression of the human factors does not confer susceptibility to HCV entry into the liver.
Hepatitis C virus (HCV) causes a chronic liver disease and affects an estimated 3% of the world population. No vaccine is available for preventing HCV, and the current treatment is often ineffective. The study of HCV has been hampered by the lack of suitable animal models. Chimpanzees are the only available in vivo experimental systems, but their use is limited by ethical concerns and high costs. HCV infection and replication in human hepatocytes has been confirmed in chimeric mice, the first reported mouse model (19) . Although various factors, such as CD81, claudin-1 (CLDN1), scavenger receptor class B type I (SR-BI), and occludin (OCLN) have been reported to mediate HCV infection (8, 11, 21, 22) , CD81 and OCLN must be human proteins to render mouse cells permissive to HCV infection (22) . CD81 alone is insufficient to confer susceptibility to HCV in CD81 transgenic mice (16) . CD81 and SR-BI interact with the E2 glycoprotein of HCV and have been suggested to play an initial role in attachment of the virus to cells (21, 23) . After attachment, receptor-virus complexes are required to enter the cells as CD81-CLDN1-HCV complexes (13, 15) and OCLN-HCV complexes (2) . Although HCV is known to enter cells via a pH-and clathrindependent endocytic pathway (3, 6, 14, 17, 26) , the precise mechanisms are not fully elucidated. In the present study, we generated CD81, CLDN1, SR-BI, OCLN transgenic mice and examined whether HCV infect the liver using HCV from a patient serum and HCV pseudoparticles (HCVpp). ing chimera mouse produced by the following method. An aggregation of 10-15 ES cells with two (C57BL/6 × DBA/2) F1 eight-cell-stage embryos, from which the zona pellucida had been removed with Tyrode's solution (Sigma-Aldrich, St. Louis, MO), was placed on a plastic dish and cultured overnight. The ES cells and eight-cell embryos developed into a single blastocyst, which was transferred to the uterus of a pseudopregnant female ICR mouse. The genetic background of the parent ES cell line, E14.1, was the 129/Ola strain. Male chimera mice were then bred with C57BL/6 female mice and the germ-line transmission of the ES cells confirmed by the agouti coat color of the offspring.
Protein detection in transgenic mouse liver. The liver was homogenized in PBS containing protease inhibitor cocktail (Sigma). The homogenate was centrifuged at 1,000 × g for 5 min at 4°C, and the pellet was dissolved in 5 volumes of NP-40 buffer (20 mM Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, and 2 mM EDTA) at 4°C for 1 h with rotation. After centrifugation at 18,500 × g for 20 min, the supernatant was used for protein analysis. The protein concentration was measured using the BCA method (Thermo Fisher Scientific, Waltham, MA). Proteins in the extracts were separated by SDS-PAGE under reducing or non-reducing conditions and transferred to a PVDF membrane (GE Healthcare, UK). The membranes were incubated first with one of four human-specific monoclonal antibodies: anti-CD81 (Millipore, Billerica, MA), anti-CLDN1 (Abnova, Taiwan), anti-SR-BI (BD Bio-
MATERIALS AND METHODS
Generation of transgenic mice. The animal procedures were approved by the experimental animal ethics committee at Hamamatsu University School of Medicine. The transgenic expression cassettes for human CD81, CLDN1, SR-BI, and OCLN were constructed as follows. The four genes were cloned from human liver total RNA (Ambion, Austin, TX) by RT-PCR using four sets of primers: 5'-ATGGG AGTGGAGGGCTGCAC-3' and 5'-CTCAGTACAC GGAGCTGTTCC-3' for CD81, 5'-ATGGCCAACG CGGGGCTGCA-3' and 5'-GTCACACGTAGTCTT TCCCGC-3' for CLDN1, 5'-ATGGGCTGCTCCGC CAAAGCG-3' and 5'-CTACAGTTTTGCTTCCTG CAGCAC-3' for SR-BI, 5'-CCATGTCATCCAGGC CTCTTG-3' and 5'-CAACTTGGCATCAGCCTTCT ATG-3' for OCLN. The PCR products were ligated into the pGEM-T easy vector (Promega, Madison, WI). The nucleotide sequence of the insert was confirmed by sequencing. The EGFP cDNA in pAlb-EGFP (28) was then replaced by CD81, CLDN1, SR-BI, or OCLN cDNA. Each expression cassette was purified to remove the vector fragment. A mixture of Alb-CD81, Alb-CLDN1, and Alb-SR-BI fragments (molar ratio = 2 : 1 : 1) or the Alb-OCLN fragment was microinjected into fertilized eggs to generate the Alb-CCS mice and Alb-O mice, respectively (Fig. 1A ). Transgenes were confirmed by Southern blot and PCR analysis. CAG-DsRed2 mice carrying the DsRed2 expression vector controlled by the CAG promoter were obtained via a DsRed2-expressing ES cell-contribut- Immunofluorescence microscopy. The staining method was described previously (5) . Cryostat liver sections 5-μm-thick were fixed in acetone-chloroform for 30 min at room temperature and used immediately after brief air drying. Sections were blocked with 10% goat serum in PBS for 30 min at room temperature and then incubated with the mouse monoclonal anti-CD81 or anti-SR-BI antibodies at 10 μg/mL in 10% goat serum in PBS overnight at 4°C. The next day, after rinsing with PBS, the sections were incubated with Alexa Fluor 594 goat anti-mouse IgG antibody for 30 min. The sections were then rinsed with PBS and counter-stained with DAPI.
Quantification of HCV RNA in sera using real-time RT-PCR. A written informed consent was obtained from the patient from whom serum was obtained. HCV (genotype 1b) from the patient's serum was injected into the mouse tail vein (0.25 mL/mouse). Two weeks after injection, sera were collected from the injected mice and HCV RNA isolated from the serum using the QIAamp Viral RNA Mini Kit (Qiagen, Germany). The number of RNA copies was analyzed by real-time RT-PCR as described previously (27) using the Step One Plus Real-Time PCR System (Applied Biosystems, Bedford, MA). In this system, the detection limit was 10 copies.
Pseudoparticle production and infection. Murine leukemia virus (MLV)-based HCVpp were generated as described previously (1) . Briefly, 8.1 μg of the Gag-Pol packaging construct, 8.1 μg of the transfer vector construct (luciferase), and 2.7 μg of the JFH-1 glycoprotein construct (pcDNAΔC-E1-E2, a kind gift from Dr. Thomas Pietschmann) were co-transfected into 293T cells using the calcium phosphate precipitation method. Supernatants containing the HCVpp were collected 40 h after transfection and passed through a 0.45-μm filter. The HCVpp were pelleted through 20% sucrose cushions by ultracentrifugation using a Beckman Coulter SW 27 rotor at 25,000 rpm for 2 h at 4°C. Hepatocytes were isolated by the two-step perfusion method described previously (10) . The isolated liver cells were suspended in DMEM containing 10% FBS, 100 IU/mL penicillin G, and 100 μg/mL streptomycin sulfate and centrifuged at 50 × g for 5 min at 4°C. This procedure was repeated four times. The purified hepatocytes were plated in a 24-well-plate The signals of specific proteins were detected using the ECL kit (Perkin-Elmer, Boston, MA). Polyclonal anti-GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used as a loading control.
Binding of E2 protein to liver sections. To obtain the E2 protein expression vector, the E2 protein region of genotype 1b (J1) was amplified by PCR using pCAGGSc60-p7 (generously provided by Dr. Yoshiharu Matsuura) as a template and the following oligonucleotides as primers: 5'-ATGGATGCA ATGAAGAGAGGGCTCTGCTGTGTGCTGCTGC TGTGTGGAGCAGTCTTCGTTTCGGCTAGCCAT ACCCGCGTGACGGGG-3' and 5'-CTAGTGATGG TGGTGATGGTGTGCTCTATCCCTGTCCTCC-3'. This plasmid DNA encoded the signal peptide of the tissue plasminogen activator (tPA) protein at the N-terminus, the E2 protein from amino acid 384 to 660 which does not contain a membrane spanning region in the middle, and 6 × His tag at the C-terminus as previously described (9, 18, 20, 24) . The PCR product was cloned into the pIRES2-EGFP vector (Clontech, Palo Alto, CA) to obtain the CMV-tPA/E2ΔH6 plasmid DNA. The nucleotide sequence was confirmed by sequencing.
The CMV-tPA/E2ΔH6 plasmid DNA was mixed with polyethylene imine (PEI) at a DNA:PEI ratio of 1 : 3 (w/w), and 0.5 mL of the mixture was added to HepG2 cells in 5 mL of culture medium in a 10-cm dish, which was then cultured in a CO 2 incubator for 4 h. The cells were then washed with PBS and cultured in DMEM without fetal bovine serum (FBS). The culture supernatant was collected 48 h after transfection and subjected to Ni-NTA His • Bind Resin (Merck, Germany) according to the manufacturer's instructions. The eluted E2 protein was concentrated using Amicon Ultra-4 (Millipore).
Cryostat liver sections 5-μm-thick were fixed in 1 : 1 acetone-chloroform (v/v) for 30 min at room temperature and used immediately after brief air drying. Sections were blocked with 10% goat serum in PBS for 30 min at room temperature and then incubated with the purified E2 protein overnight at 4°C. The next day, after washing with PBS, the sections were incubated with mouse monoclonal anti-hepatitis C virus E2 antibody (Abcam, UK) for 1 h at room temperature and then with Alexa Fluor 594 goat anti-mouse IgG antibody (Invitrogen, Carlsbad, CA). Sections were counter-stained with DAPI (Dojindo, Japan).
to bind the CD81 and SR-BI proteins (21, 23) . Therefore, soluble E2 protein was expected to bind to liver sections from Alb-CCSO mice. After incubating the liver sections with the purified E2 protein, mouse monoclonal anti-E2 antibody, and Alexa Fluor 594 goat anti-mouse IgG antibody, the cellcell borders were clearly stained ( Fig. 2A, right) . In contrast, a background level of E2 binding was detected in wild-type liver ( Fig. 2A, left) , indicating that E2 binding was prominent in liver sections from Alb-CCSO mice. Next, we tried to detect CD81 and SR-BI proteins in Alb-CCSO mice. The CD81 and SR-BI proteins were mainly stained in the cell-cell borders (Fig. 2B , right panels). In wild-type liver, little staining was observed using antibodies against human proteins (Fig. 2B, left panels) . The results indicate that E2 protein can bind the CD81 and SR-BI proteins in Alb-CCSO mice, and that the site of the E2 binding is similar to that of CD81 and SR-BI proteins. We also tried to detect the CLDN1 and OCLN proteins in Alb-CCSO mice. CLDN1 was detected mainly in cell-cell junction, but OCLN was difficult to be determined due to a low specificity and a high background of anti-human OCLN antibody (data not shown).
Infection of mice with HCV from patient serum
Because the E2 protein specifically bound the Alb-CCSO liver sections, we infected the Alb-CCSO mice with HCV from patient serum. HCV has been shown to infect the human hepatocytes in the chimeric liver of immunocompromised mice and maintain HCV in the mouse serum from 1 to 5 weeks post-infection (19) . Immunocompetent mice, such as the Alb-CCSO mice, can elicit an immune response; therefore, the long-term persistence of HCV infection is not expected. To test this assumption, we injected HCV from a patient (5.7 Log IU/mL) into Alb-CCSO mice (n = 5) and wild-type mice (n = 5), and collected the mouse serum 2 weeks after infection. The RNA copy number in the injected sample was approximately 1.2 × 10 5 copies, but the copy numbers for the mouse serum samples were under the detection level (Table 1 ). This finding indicates that the expression of the four human factors in mouse hepatocytes did not confer susceptibility to HCV infection and production in vivo.
HCVpp infection of primary hepatocytes from Alb-CCSO mice
The process of HCV infection has several steps. The first step is HCV entry into hepatocytes. The second DMEM with 10% FBS on the same day as the isolation of the primary hepatocytes. On the next day, the cells were infected with HCVpp overnight. The medium was changed the next day and the cells cultured for an additional 48 h. The luciferase activity of the cell extract was measured according to the manufacturer's instructions (Promega).
Fusion of mouse and human hepatocytes.
To establish a stable EGFP-expressing Hep3B cell line, Hep3B cells were transfected with pEGFP-N1 DNA (Clontech) and cloned in DMEM containing G418 (0.4 mg/ mL) using the cylinder technique. Mouse hepatocytes were isolated from the CAG-DsRed2 mice using the two-step perfusion method as described above. The DsRed2-labelled hepatocytes and EGFPexpressing Hep3B cells were fused (1.4 × 10 7 cells each) using PEG4000 as described previously (12) . The fused cells were resuspended in DMEM with 10% FBS and subjected to sorting with BD FACSAria (BD Biosciences). DsRed2 and EGFP doublepositive cells were used for the HCVpp infection assay as described above.
RESULTS

Generation of transgenic mice
The expression of albumin starts in early fetal hepatocytes (E12) and peaks in adult hepatocytes at 4 weeks (25) . Therefore, the expression of the transgene was thought to have no crucial effect on liver development and we got apparently healthy and fertile mice. For Alb-CCS mice, 25 founder mice were generated, six of which were positive for transgene integration. Two of these six mice were positive for the three human proteins (CD81, CLDN1, and SR-BI). For Alb-O mice, 90 founder mice were generated, eight of which were positive for transgene integration. Two of these eight mice were positive for the OCLN protein. We chose mice expressing higher amounts of the proteins and crossed the Alb-CCS and Alb-O mice, finally obtaining Alb-CCSO mice. The protein expression was determined by Western blot (Fig. 1B) . The anti-human CLDN1 antibody cross-reacted with the mouse protein, but human CLDN1 was prominent in Alb-CCSO mice. We also detected the large amount of human CLDN1 mRNA in addition to the mouse Cldn1 mRNA in the liver of Alb-CCSO mice using RT-PCR analysis (data not shown).
Binding of soluble E2 protein to the liver section
The truncated soluble E2 protein has been reported step is the synthesis of viral proteins and replication of the genomic RNA. The last step is virus assembly and budding from the host cells. HCV could not infect the Alb-CCSO mice as shown above, but HCV can enter the mouse hepatocytes expressing the four human factors. To determine this hypothesis, we prepared HCVpp as described above. The HCVpp we used have HCV E1/E2 proteins in the envelope instead of MLV envelope protein, and a luciferase expression unit in the RNA genome. To determine the specificity of HCVpp entry, we also made a pseudoparticle harbouring the VSV-G protein (positive control) and no envelope psudoparticle (negative control) and infected Hep3B cells (data not shown). Primary hepatocytes were isolated using the collagenase perfusion method. The next day, cells were Table 1 HCV RNA copy numbers in sera Wild-type mice (n = 5) < 10 copies/100 μL CCSO mice (n = 5) < 10 copies/100 μL Injected human serum 1.2 × 10 5 copies/250 μL The experiments presented here demonstrated that CD81, CLDN1, SR-BI, and OCLN expression in the hepatocytes of transgenic mice does not confer susceptibility to HCV infection in vivo and in vitro.
The expression of these four factors in a nonpermissive mouse embryonic fibroblast cell line, NIH3T3, makes the cells permissive to HCV entry. However, the infectivity is quite low in a mouse hepatocellular carcinoma cell line, Hepa1.6, expressing these four factors (22) . The result in the latter cells and our results that the primary mouse hepatocytes expressing the four factors were non-permissive to HCV entry might indicate that a mouse hepatocyte character is not suitable for HCV entry.
There are two possibilities for no susceptibility to HCV entry; additional factor(s) are necessary for HCV entry or dominant negative restriction factor(s) are present in the mouse hepatocytes, but not in NIH3T3 cells. To evaluate the possibility of dominant negative factors, we performed the cell fusion experiment. HCV entry into the fused cells was 35-fold less than that into Hep3B cells. As this result suggests the possibility of dominant negative factor(s) in the mouse hepatocytes, further analysis is required to identify the dominant restriction factor(s). However, our results did not deny the presence of additional essential factor(s) in the human hepatocytes.
As expected, transgenic expression of CD81 and SR-BI surely enhanced the binding of E2 protein to the liver sections in our experiments. The key factors of human origin for post-binding events, including caveolin and Rab34 in Coxsackievirus entry, are thought to be absent in mouse primary hepatocytes (7). One study described that transferrin receptor 2 (TfR2) is associated with CD81 protein, and that infected with HCVpp overnight and the luciferase activity of the cell extracts measured 72 h after infection (Fig. 3A) . HCVpp infected the Hep3B cells efficiently, and the Hep3B cell extract exhibited high luciferase activity. However, the luciferase activity of the cell extracts of primary hepatocytes from Alb-CCSO mice was negligibly low, as was that of primary hepatocytes from wild-type mice (Fig. 3A) . Based on our data on in vivo and in vitro infection, we concluded that the expression of the four human proteins in the mouse hepatocytes does not confer susceptibility to HCV entry into hepatocytes. Finally, we tried to determine whether the mouse hepatocytes expressed inhibitory factor(s) to HCV entry. The Hep3B and primary hepatocyte fused cells were sorted by FACS. Mouse hepatocytes have autofluorescence; therefore, the EGFP and Ds-Red double-positive population was collected and the autofluorescent population excluded. We infected the fused cells with HCVpp. The luciferase activity of the fused cells was 35-fold lower than that of Hep3B cells (Fig. 3B) , suggesting that the mouse hepatocytes have inhibitory factor(s) to HCV entry.
DISCUSSION
We succeeded in making transgenic mice in which the four human proteins were expressed in the mouse hepatocytes. The E2 protein of HCV highly bound to the liver sections of transgenic mice comparing to wild-type mice. We also demonstrated that the E2-binding site was similar to those of HCV receptors (CD81 and SR-BI) in the transgenic mice and interpreted that the E2-receptor complex would be near CLDN1 and OCLN at the tight junction. TfR2 is responsible for an endosomal pathway (4). To examine whether these factors interact with HCV might be important. Many papers have reported the various receptors or factors and the susceptibility to HCV in the established or transfected cells. Comparing the expression and interaction of receptors/factors between permissive and non-permissive cells may provide a breakthrough in the molecular understanding of HCV entry. Our data demonstrated that the expression of CD81, CLDN1, SR-BI, and OCLN in the transgenic liver was not enough to confer susceptibility to HCV entry. This report provides an insight into the generation of an HCV-infectible mouse.
